Image source

Canopy Growth Corporation (CGC), a constituent in the Canadian Cannabis LPs Portfolio, went DOWN 12.9% between June 6 and June 13, hurt by three main factors, namely:

1. Disappointing Q4 U.S. medical rollout:  Although CGC saw solid Canadian medical growth, its ambitious U.S. “Spectrum Reserve” launch fell short of initial projections. Management lowered its forecast for U.S. revenues in FY26, citing slower-than-expected licensing approvals and weaker dispenser uptake.
2. Sector-wide profit taking: The 5 stocks in the Canadian Cannabis LPs Portfolio had gone UP 25% since the end of March with CGC, itself, UP 72% and with that many institutional holders trimmed CGC exposure to lock in gains.
3. Lingering Canada recreation legalization uncertainty: With the Ontario government hinting at potential cannabis tax hikes (to cover budget deficits) and retail licensing pauses, investors fretted that higher levies and slower store approvals could crimp adult-use volumes and margin recovery.

About Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products such as dried flower and pre-rolled joints; extracts and concentrates such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, and concentrates in Canada, Germany, and Australia.

Stock Price Forecast

Only 1 analyst has a 12-month price forecast for CGC with a target of $2.00, which represents a 35.14% increase from the current stock price of $1.48.

Analyst Ratings

The analyst rating for Canopy Growth stock is "Sell".

More By This Author:

Quantum Computing Inc. Surged Another 22% This Week; Here's Why
7 Model AI Hardware Stock Portfolios Were Up 2.3%, On Average, Week-Ending June 13th; Up 6.1% MTD
AI-Focused Drug Discovery Company, AbCellera, Up 21% W/e June 6th